Hints and tips:
Related Special Reports
...So, Sompo Holdings, one of Japan’s biggest insurance companies and the operator of about 280 care homes across the country, has turned to technology to address the problem....
...It exited its position in generic drugs maker Teva and sold more than 70 per cent of its remaining shares in AbbVie and Bristol-Myers Squibb....
...“We plan to continue investigating the validity of the insurance policies,” Endo said....
...In recent years, however, there has been a shift towards more generic indices that purport to provide an offering similar to traditional benchmarks, such as the S&P 500....
...The generic reasons are that it is highly expensive and time-consuming. With the Chapter 11 absolute priority rule, the process has proven even tougher for companies such as Hertz. sujeet.indap@ft.com...
...AbbVie has dropped the global patent protection for the drug, which is a relatively mature one, paving the way for cheaper generics....
...The superhero caper El Vecino (The Neighbor) started rolling again in Madrid almost two weeks ago, after holding surreal rehearsals with cast wearing face shields*....
...That means the real amount being booked by generic drugmakers that sell the medicine is often below $45.46, after allowing for a cut taken by the wholesaler....
...The combination will be 57 per cent owned by Pfizer shareholders, with Mylan investors holding the remaining 43 per cent....
...Total ETF holdings of gold are 20% higher than they were when we worried about positioning back in January....
...Many of the defendants have teamed up to offer $48bn to settle these suits — but so far, many states are holding out for more....
...Chinese companies are producing better quality generics, winning approvals even in the US....
...While there has been some speculation that the unit could still be spun off, Wednesday’s reorganisation suggests Pfizer will be holding on to the business — at least for the time being....
...The pair own 49 per cent of the company between them, with other staff holding 10 per cent. The rest is free float. Both executives are focused on succession....
...Instead of emphasising that issue, discussion of these matters remained restricted to the same old mind-numbing generics about memories and crisis skill-sets depreciating over time, need to scan for “the...
...This has fuelled intensifying competition between India and Bangladesh in the field of generic and bulk drugs....
...The expansion of outbound deals to midsized players such as Sawai illustrates that acquisitions are now key for Japan Inc....
...Teva, the world’s largest generic drugmaker, has previously announced plans to shed 14,000 jobs by 2019 as it seeks to lower expenses and last week forecast a sharp drop in revenues for 2018....
...It is also suing Cognizant Technology Solutions and is co-lead plaintiff in a case against Allergan over an alleged generic drug price-fixing scheme....
...It comes after the drugmaker took a write down of nearly $2bn on its Teva holding in the first quarter....
...Revlimid, its top cancer medicine, accounts for almost two-thirds of revenues, but will face competition from cheaper generic rivals from 2022 at the latest....
...Drugmakers already say that PBMs, insurers and wholesalers are collaborating in ways that is hurting their margins, and generic drugmakers such as Teva and Mylan have blamed more powerful customers for price...
...Although Amazon has kept quiet about its plans, it has become increasingly interested in healthcare in recent months, holding meetings with industry executives and making several senior hires from insurers...
...The case brought by Louisiana’s attorney-general against Pfizer had nothing to do with the opioid epidemic, and instead alleged that the company had tried to stop the introduction of copycat generic versions...
...“We immediately saw the value in sovereigns holding patents . . . so we started planning strategies to reap the value of that arbitrage,” says Mr Shore. “We approached several tribes with the concept....
International Edition